220 related articles for article (PubMed ID: 17690594)
41. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to make the decision to resort to an APAP)].
Chéreau I; Gorwood P; Mouchabac S
Encephale; 2009 Jan; Suppl 3():S97-100. PubMed ID: 19268186
[No Abstract] [Full Text] [Related]
42. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
[TBL] [Abstract][Full Text] [Related]
43. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial.
Berk M; Gama CS; Sundram S; Hustig H; Koopowitz L; D'Souza R; Malloy H; Rowland C; Monkhouse A; Monkhouse A; Bole F; Sathiyamoorthy S; Piskulic D; Dodd S
Hum Psychopharmacol; 2009 Apr; 24(3):233-8. PubMed ID: 19330802
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.
Emsley R; Berwaerts J; Eerdekens M; Kramer M; Lane R; Lim P; Hough D; Palumbo J
Int Clin Psychopharmacol; 2008 Nov; 23(6):343-56. PubMed ID: 18854723
[TBL] [Abstract][Full Text] [Related]
45. [Schizophrenics in the doctor's office. Diagnostic and therapeutic aspects].
Bottlender R; Möller HJ
MMW Fortschr Med; 2004 May; 146 Spec No 2():19-23. PubMed ID: 15376697
[TBL] [Abstract][Full Text] [Related]
46. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Current status of recommendations for treatment with an APAP].
Buis C; Gourion D; Vaiva G
Encephale; 2009 Jan; Suppl 3():S91-5. PubMed ID: 19268185
[No Abstract] [Full Text] [Related]
47. Duration of untreated psychosis and it's effect on the functional outcome in schizophrenia - preliminary results.
Sarotar BN; Pesek MB; Agius M; Pregelj P; Kocmur M
Psychiatr Danub; 2008 Jun; 20(2):179-83. PubMed ID: 18587288
[TBL] [Abstract][Full Text] [Related]
48. Long-term effects of risperidone versus haloperidol on verbal memory, attention, and symptomatology in schizophrenia.
Rémillard S; Pourcher E; Cohen H
J Int Neuropsychol Soc; 2008 Jan; 14(1):110-8. PubMed ID: 18078537
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
[TBL] [Abstract][Full Text] [Related]
50. Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia.
Rocca P; Montemagni C; Castagna F; Giugiario M; Scalese M; Bogetto F
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):373-9. PubMed ID: 19211031
[TBL] [Abstract][Full Text] [Related]
51. Strategies for the long-term treatment of schizophrenia: real-world lessons from the CATIE trial.
Meyer JM
J Clin Psychiatry; 2007; 68 Suppl 1():28-33. PubMed ID: 17286525
[TBL] [Abstract][Full Text] [Related]
52. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to prescribe an APAP?].
Dassa D; Lacambre M; Vacheron MN
Encephale; 2009 Jan; Suppl 3():S109-13. PubMed ID: 19268179
[No Abstract] [Full Text] [Related]
53. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
54. One-year outcome and its prediction in first-episode schizophrenia--a naturalistic study.
Bachmann S; Bottmer C; Schroder J
Psychopathology; 2008; 41(2):115-23. PubMed ID: 18059113
[TBL] [Abstract][Full Text] [Related]
55. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia.
Leucht S; Heres S
J Clin Psychiatry; 2006; 67 Suppl 5():3-8. PubMed ID: 16822090
[TBL] [Abstract][Full Text] [Related]
56. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
57. Assessing and measuring nonresponse in schizophrenia.
Kane JM
J Clin Psychiatry; 2012 Jan; 73(1):e04. PubMed ID: 22316583
[TBL] [Abstract][Full Text] [Related]
58. Course and long-term treatment of schizophrenic psychoses.
Möller HJ
Pharmacopsychiatry; 2004 Nov; 37 Suppl 2():126-35. PubMed ID: 15546064
[TBL] [Abstract][Full Text] [Related]
59. [Therapeutic goal and pharmacotherapy according to clinical stages of schizophrenia].
Furuhashi K; Iwata N
Nihon Rinsho; 2013 Apr; 71(4):635-40. PubMed ID: 23678592
[TBL] [Abstract][Full Text] [Related]
60. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?
Buckley PF; Stahl SM
Acta Psychiatr Scand; 2007 Feb; 115(2):93-100. PubMed ID: 17244172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
